| 周咏梅 林元龙 沈平 汤立 袁刚.雷公藤多苷联合吗替麦考酚酯多靶点免疫抑制治疗难治性
肾病综合症的疗效评估[J].现代生物医学进展英文版,2014,14(3):532-535. |
| 雷公藤多苷联合吗替麦考酚酯多靶点免疫抑制治疗难治性
肾病综合症的疗效评估 |
| Effect Evaluation on Multi-Target Immunosuppressive Therapy withTripterygiumGlycosides Combined with Mycophenolate Mofetil forRefractory Nephritic Syndrome |
| |
| DOI： |
| 中文关键词: 难治性肾病综合症 多靶点免疫抑制 雷公藤多苷 吗替麦考酚酯 |
| 英文关键词: Refractory nephritic syndrome Multi-target immunosuppressive therapy Tripterygium glycosides Mycophenolate
mofetil |
| 基金项目: |
|
| Hits: 632 |
| Download times: 1018 |
| 中文摘要: |
| 目的：探讨雷公藤多苷联合吗替麦考酚酯（MMF）多靶点免疫抑制治疗难治性肾病综合症（RNS）的临床疗效及安全性。方
法：将76 例RNS 患者随机分为三组，A 组（30 例）采用雷公藤多苷联合MMF 多靶点免疫抑制疗法，B 组（29 例）采用环磷酰胺
（CTX）冲击疗法，C 组（27 例）采用MMF疗法，总疗程均为6 个月。比较分析三组的临床疗效、肾功能、复发情况及不良反应。结
果：A 组的总有效率为73.3%，显著高于B 组48.3%，C组44.4%（P<0.05）；治疗后，三组的肾功能指标均有所改善，与B 组和C 组
比较，A 组尿蛋白定量、血肌酐（Scr）显著降低，血清白蛋白（ALB）显著升高（P<0.05）；A组的复发率(0%)显著低于B 组(21.4%)和
C 组(15.4%)（P<0.05）。A组不良反应发生率与B 组、C 组之间的差异无统计学意义(P>0.05)。结论：雷公藤多苷联合MMF多靶点
治疗RNS 安全有效，可减少免疫抑制剂的剂量，提高缓解率，改善肾功能，且不良反应少。 |
| 英文摘要: |
| Objective:Toexplore clinical efficacyandsafetyonmulti-target immunosuppressive therapywithtripterygiumglycosides
combined with mycophenolate mofetil (MMF) for refractory nephritic syndrome (RNS).Methods:76 cases of RNS patients were
randomly divided into three groups. GroupA (N=30) was given multi-target immunosuppressive therapy with tripterygium glycosides
combined with MMF, Group B (N=29) was given cyclophosphamide (CTX) pulse therapy, and Group C (N=27) was given MMF,
respectively. The clinical effect, renal function, recurrence rate and side effect were observed.Results:The clinical effect in Group A was
73.3%, was significantly higher than that in Group B 48.3%and Group C 44.4%(P<0.05). The renal function in all groups was improved
after treatment, while the levels of 24 h proteinuria, Scr were lower and ALB was higher significantly in Group A compared with those in
Group B and Group C (P<0.05). The recurrence rate in Group A (0%) was significantly lower than that in Group B 21.4 %and Group C
15.4 %. There was no significant difference on the side effect among the three groups (P>0.05).Conclusion:It is effective and safe of
multi-target immunosuppressive therapy with tripterygium glycosides and MMF for RNS, it can contribute to reduce the dosage of
immunosuppressant, improve remission rate and renal function, and has a relative lower side effects. |
|
View Full Text
View/Add Comment Download reader |
| Close |
